Krensavage Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Krensavage Asset Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Hold	339,532	–	–	4.05%	8
2025 Q4	$12.2M	Hold	339,532	–	–	4.3%	10
2025 Q3	$8.19M	Sell	339,532 -634,942	-65%	-$13.3M	3.49%	11
2025 Q2	$14.4M	Buy	974,474 +9,106	+0.9%	+$106K	7.6%	7
2025 Q1	$9.2M	Buy	965,368 +29,688	+3%	+$312K	5.09%	8
2024 Q4	$11.6M	Buy	935,680 +233,807	+33%	+$2.41M	6.88%	7
2024 Q3	$6.84M	Buy	+701,873	New	+$8.22M	3.83%	10

Other funds holding INDV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Krensavage Asset Management's INDV Position: Q1 2026 in Review

Krensavage Asset Management held its Indivior Pharmaceuticals (INDV) position steady in Q1 2026 at 339,532 shares worth $10.3M. The position accounts for 4.05% of the portfolio, ranked #8.

Krensavage Asset Management first reported a position in INDV in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.4M in Q2 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

Krensavage Asset Management held 339,532 shares of Indivior Pharmaceuticals worth $10.3M as of Q1 2026.
Krensavage Asset Management left its Indivior Pharmaceuticals share count unchanged in Q1 2026.
Indivior Pharmaceuticals made up 4.05% of Krensavage Asset Management's portfolio in Q1 2026, its #8 holding.
Krensavage Asset Management first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Krensavage Asset Management's Indivior Pharmaceuticals position peaked at $14.4M in Q2 2025.
289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.